178 related articles for article (PubMed ID: 37625013)
1. Anti-HIV drugs lopinavir/ritonavir activate bitter taste receptors.
Chen S; Zhou X; Lu Y; Xu K; Wen J; Cui M
Chem Senses; 2023 Jan; 48():. PubMed ID: 37625013
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
6. Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
Saeed AM; Schmidt JM; Munasinghe WP; Vallabh BK; Jarvis MF; Morris JB; Mostafa NM
J Pharm Sci; 2021 Dec; 110(12):3963-3968. PubMed ID: 34530003
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania.
Jiwa NA; Ketang'enyi E; Nganyanyuka K; Mbwanji R; Mwenisongole D; Masuka E; Brown M; Charles M; Mwasomola DL; Nyangalima T; Olomi W; Komba L; Gwimile J; Kasambala B; Mwita L
PLoS One; 2024; 19(1):e0292424. PubMed ID: 38165867
[TBL] [Abstract][Full Text] [Related]
8. Use of Adult Sensory Panel to Study Individual Differences in the Palatability of a Pediatric HIV Treatment Drug.
Mennella JA; Mathew PS; Lowenthal ED
Clin Ther; 2017 Oct; 39(10):2038-2048. PubMed ID: 28923290
[TBL] [Abstract][Full Text] [Related]
9. Activation of specific bitter taste receptors by olive oil phenolics and secoiridoids.
Cui M; Chen B; Xu K; Rigakou A; Diamantakos P; Melliou E; Logothetis DE; Magiatis P
Sci Rep; 2021 Nov; 11(1):22340. PubMed ID: 34785711
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.
Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN;
Medicine (Baltimore); 2020 Sep; 99(39):e22352. PubMed ID: 32991450
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
[TBL] [Abstract][Full Text] [Related]
12. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Pham K; Li D; Guo S; Penzak S; Dong X
J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
Alves ÉAR; de Miranda MG; Borges TK; Magalhães KG; Muniz-Junqueira MI
Int Immunopharmacol; 2015 Feb; 24(2):314-324. PubMed ID: 25545854
[TBL] [Abstract][Full Text] [Related]
15. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
[TBL] [Abstract][Full Text] [Related]
16. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
Ramos JT; De José MI; Dueñas J; Fortuny C; González-Montero R; Mellado MJ; Mur A; Navarro M; Otero C; Pocheville I; Muñoz-Fernández MA; Cabrero E;
Pediatr Infect Dis J; 2005 Oct; 24(10):867-73. PubMed ID: 16220083
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
[TBL] [Abstract][Full Text] [Related]
19. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
